Anti-proliferation effect of 3-amino-2-imino-3,4-dihydro-2H-1,3- benzothiazin-4-one (BJ-601) on human vascular endothelial cells: G0/G1 p21-associated cell cycle arrest

Chung Hsun Yu, Jender Wu, Yi Fan Su, Pei Yin Ho, Yu Chih Liang, Ming Thau Sheu, Wen Sen Lee

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

The aim of this study was to examine the anti-proliferation effect of 3-amino-2-imino-3,4-dihydro-2H-1,3-benzothiazin-4-one (BJ-601) on human vascular endothelial cells and its possible molecular mechanism underlying. Our data showed that BJ-601 at a range of concentrations (0-40 μM) dose- and time-dependently decreased cell number in cultured human dermal microvascular endothelial cells (HDMVECs), but not human fibroblasts. The BJ-601-induced growth inhibition in HDMVECs was reversible. [3H]thymidine incorporation demonstrated that BJ-601 arrested the HDMVECs at the G0/G1 phase of the cell cycle. Western blot analysis revealed that BJ-601 (0-40 μM) dose-dependently increased the levels of the protein p21, but not of p27, p53, cyclins A, D1, D3 and E, cyclin-dependent kinase 2 (CDK2), and CDK4 in HDMVECs. Immunoprecipitation showed that the formation of the CDK2-p21 complex, but not CDK2-p27, CDK4-p21 and CDK4-p27 complexes, was increased in the BJ-601-treated HDMVECs. Kinase assay further demonstrated that CDK2, but not CDK4, kinase activity was decreased in a dose-dependent manner in the BJ-601-treated HDMVECs. Pretreatment of HDMVECs with a p21 antisense oligonucleotide, which blocked the expression of p21 protein, reversed the BJ-601-induced inhibition of [ 3H]thymidine incorporation into HDMVECs. Moreover, cotreatment of the endothelial cells with protein kinase C (PKC) inhibitor, staurosporine, prevented the BJ-601-induced decrease of [3H]thymidine incorporation into HDMVECs. Administration of BJ-601 dose-dependently inhibited capillary-like tube formation of HDMVECs in Matrigel. In conclusion, these data suggest that BJ-601 inhibits HDMVECs proliferation by increasing the level of p21 protein, which in turn inhibits CDK2 kinase activity, and finally causes retardation of the cell cycle at the G0/G1 phase.

Original languageEnglish
Pages (from-to)1907-1916
Number of pages10
JournalBiochemical Pharmacology
Volume67
Issue number10
DOIs
Publication statusPublished - May 15 2004

Fingerprint

Endothelial cells
Cell Cycle Checkpoints
Endothelial Cells
Cells
Cyclin-Dependent Kinase 2
Skin
Thymidine
Cell Cycle Resting Phase
Phosphotransferases
G1 Phase
3-amino-2-imino-3,4-dihydro-2H-1,3-benzothiazin-4-one
Cell Cycle
Cyclin A
Cyclin E
Proteins
Staurosporine
Protein C Inhibitor
Antisense Oligonucleotides
Cyclin D1
Cell proliferation

Keywords

  • 3-amino-2-imino-3,4-dihydro-2H-1,3-benzothiazin-4-one
  • BJ-601
  • CDK
  • cyclin-dependent kinase
  • HDMVECs
  • HEPES
  • human dermal microvascular endothelial cells
  • human umbilical vein endothelial cells
  • HUVECs
  • PKC
  • protein kinase C

ASJC Scopus subject areas

  • Pharmacology

Cite this

@article{4b312d60167c46a9b0d24c8404d7e1ba,
title = "Anti-proliferation effect of 3-amino-2-imino-3,4-dihydro-2H-1,3- benzothiazin-4-one (BJ-601) on human vascular endothelial cells: G0/G1 p21-associated cell cycle arrest",
abstract = "The aim of this study was to examine the anti-proliferation effect of 3-amino-2-imino-3,4-dihydro-2H-1,3-benzothiazin-4-one (BJ-601) on human vascular endothelial cells and its possible molecular mechanism underlying. Our data showed that BJ-601 at a range of concentrations (0-40 μM) dose- and time-dependently decreased cell number in cultured human dermal microvascular endothelial cells (HDMVECs), but not human fibroblasts. The BJ-601-induced growth inhibition in HDMVECs was reversible. [3H]thymidine incorporation demonstrated that BJ-601 arrested the HDMVECs at the G0/G1 phase of the cell cycle. Western blot analysis revealed that BJ-601 (0-40 μM) dose-dependently increased the levels of the protein p21, but not of p27, p53, cyclins A, D1, D3 and E, cyclin-dependent kinase 2 (CDK2), and CDK4 in HDMVECs. Immunoprecipitation showed that the formation of the CDK2-p21 complex, but not CDK2-p27, CDK4-p21 and CDK4-p27 complexes, was increased in the BJ-601-treated HDMVECs. Kinase assay further demonstrated that CDK2, but not CDK4, kinase activity was decreased in a dose-dependent manner in the BJ-601-treated HDMVECs. Pretreatment of HDMVECs with a p21 antisense oligonucleotide, which blocked the expression of p21 protein, reversed the BJ-601-induced inhibition of [ 3H]thymidine incorporation into HDMVECs. Moreover, cotreatment of the endothelial cells with protein kinase C (PKC) inhibitor, staurosporine, prevented the BJ-601-induced decrease of [3H]thymidine incorporation into HDMVECs. Administration of BJ-601 dose-dependently inhibited capillary-like tube formation of HDMVECs in Matrigel. In conclusion, these data suggest that BJ-601 inhibits HDMVECs proliferation by increasing the level of p21 protein, which in turn inhibits CDK2 kinase activity, and finally causes retardation of the cell cycle at the G0/G1 phase.",
keywords = "3-amino-2-imino-3,4-dihydro-2H-1,3-benzothiazin-4-one, BJ-601, CDK, cyclin-dependent kinase, HDMVECs, HEPES, human dermal microvascular endothelial cells, human umbilical vein endothelial cells, HUVECs, PKC, protein kinase C",
author = "Yu, {Chung Hsun} and Jender Wu and Su, {Yi Fan} and Ho, {Pei Yin} and Liang, {Yu Chih} and Sheu, {Ming Thau} and Lee, {Wen Sen}",
year = "2004",
month = "5",
day = "15",
doi = "10.1016/j.bcp.2004.02.004",
language = "English",
volume = "67",
pages = "1907--1916",
journal = "Biochemical Pharmacology",
issn = "0006-2952",
publisher = "Elsevier Inc.",
number = "10",

}

TY - JOUR

T1 - Anti-proliferation effect of 3-amino-2-imino-3,4-dihydro-2H-1,3- benzothiazin-4-one (BJ-601) on human vascular endothelial cells

T2 - G0/G1 p21-associated cell cycle arrest

AU - Yu, Chung Hsun

AU - Wu, Jender

AU - Su, Yi Fan

AU - Ho, Pei Yin

AU - Liang, Yu Chih

AU - Sheu, Ming Thau

AU - Lee, Wen Sen

PY - 2004/5/15

Y1 - 2004/5/15

N2 - The aim of this study was to examine the anti-proliferation effect of 3-amino-2-imino-3,4-dihydro-2H-1,3-benzothiazin-4-one (BJ-601) on human vascular endothelial cells and its possible molecular mechanism underlying. Our data showed that BJ-601 at a range of concentrations (0-40 μM) dose- and time-dependently decreased cell number in cultured human dermal microvascular endothelial cells (HDMVECs), but not human fibroblasts. The BJ-601-induced growth inhibition in HDMVECs was reversible. [3H]thymidine incorporation demonstrated that BJ-601 arrested the HDMVECs at the G0/G1 phase of the cell cycle. Western blot analysis revealed that BJ-601 (0-40 μM) dose-dependently increased the levels of the protein p21, but not of p27, p53, cyclins A, D1, D3 and E, cyclin-dependent kinase 2 (CDK2), and CDK4 in HDMVECs. Immunoprecipitation showed that the formation of the CDK2-p21 complex, but not CDK2-p27, CDK4-p21 and CDK4-p27 complexes, was increased in the BJ-601-treated HDMVECs. Kinase assay further demonstrated that CDK2, but not CDK4, kinase activity was decreased in a dose-dependent manner in the BJ-601-treated HDMVECs. Pretreatment of HDMVECs with a p21 antisense oligonucleotide, which blocked the expression of p21 protein, reversed the BJ-601-induced inhibition of [ 3H]thymidine incorporation into HDMVECs. Moreover, cotreatment of the endothelial cells with protein kinase C (PKC) inhibitor, staurosporine, prevented the BJ-601-induced decrease of [3H]thymidine incorporation into HDMVECs. Administration of BJ-601 dose-dependently inhibited capillary-like tube formation of HDMVECs in Matrigel. In conclusion, these data suggest that BJ-601 inhibits HDMVECs proliferation by increasing the level of p21 protein, which in turn inhibits CDK2 kinase activity, and finally causes retardation of the cell cycle at the G0/G1 phase.

AB - The aim of this study was to examine the anti-proliferation effect of 3-amino-2-imino-3,4-dihydro-2H-1,3-benzothiazin-4-one (BJ-601) on human vascular endothelial cells and its possible molecular mechanism underlying. Our data showed that BJ-601 at a range of concentrations (0-40 μM) dose- and time-dependently decreased cell number in cultured human dermal microvascular endothelial cells (HDMVECs), but not human fibroblasts. The BJ-601-induced growth inhibition in HDMVECs was reversible. [3H]thymidine incorporation demonstrated that BJ-601 arrested the HDMVECs at the G0/G1 phase of the cell cycle. Western blot analysis revealed that BJ-601 (0-40 μM) dose-dependently increased the levels of the protein p21, but not of p27, p53, cyclins A, D1, D3 and E, cyclin-dependent kinase 2 (CDK2), and CDK4 in HDMVECs. Immunoprecipitation showed that the formation of the CDK2-p21 complex, but not CDK2-p27, CDK4-p21 and CDK4-p27 complexes, was increased in the BJ-601-treated HDMVECs. Kinase assay further demonstrated that CDK2, but not CDK4, kinase activity was decreased in a dose-dependent manner in the BJ-601-treated HDMVECs. Pretreatment of HDMVECs with a p21 antisense oligonucleotide, which blocked the expression of p21 protein, reversed the BJ-601-induced inhibition of [ 3H]thymidine incorporation into HDMVECs. Moreover, cotreatment of the endothelial cells with protein kinase C (PKC) inhibitor, staurosporine, prevented the BJ-601-induced decrease of [3H]thymidine incorporation into HDMVECs. Administration of BJ-601 dose-dependently inhibited capillary-like tube formation of HDMVECs in Matrigel. In conclusion, these data suggest that BJ-601 inhibits HDMVECs proliferation by increasing the level of p21 protein, which in turn inhibits CDK2 kinase activity, and finally causes retardation of the cell cycle at the G0/G1 phase.

KW - 3-amino-2-imino-3,4-dihydro-2H-1,3-benzothiazin-4-one

KW - BJ-601

KW - CDK

KW - cyclin-dependent kinase

KW - HDMVECs

KW - HEPES

KW - human dermal microvascular endothelial cells

KW - human umbilical vein endothelial cells

KW - HUVECs

KW - PKC

KW - protein kinase C

UR - http://www.scopus.com/inward/record.url?scp=2342539769&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2342539769&partnerID=8YFLogxK

U2 - 10.1016/j.bcp.2004.02.004

DO - 10.1016/j.bcp.2004.02.004

M3 - Article

C2 - 15130767

AN - SCOPUS:2342539769

VL - 67

SP - 1907

EP - 1916

JO - Biochemical Pharmacology

JF - Biochemical Pharmacology

SN - 0006-2952

IS - 10

ER -